AstraZeneca PLC to Discuss Strategic Collaboration in Oncology of Trastuzumab Deruxtecan (DS-8201) with Daiichi Sankyo Co Ltd Call Transcript
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to today's AstraZeneca Management Conference Call. (Operator Instructions) I must advise you that this conference is being recorded today, Friday, 29th of March 2019.
And without any further delay, I would now like to turn the conference over to presenter today, Chief Executive Officer, Pascal Soriot. Please go ahead, sir.
Thank you, operator. Good morning, good afternoon, everybody. Thank you very much for joining us today. We wanted to share with you a short presentation about the very exciting project we've just announced today. If you move to Slide 2, this is our forward-looking statement. Slide 3, today, I will share the presentation with José Baselga, who is our Executive Vice President of Research and Development Oncology; Dave Fredrickson, who is our EVP of Oncology; and Marc Dunoyer, our CFO.
If we move to Slide 4, which is a summary of the deal we've announced, we see DS-8201 as a transformative
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
